Anti-Mouse TIM-1 (CD365) – Purified in vivo GOLD™ Functional Grade

Full-length TIM-1-Ig containing both the IgV and mucin domains

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Functional grade preclinical antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

RMT1-10 activity is directed against mouse TIM-1 (CD365).

TIM-1 is a member of the T cell immunoglobulin mucin gene family and encodes a cell-surface glycoprotein consisting of an immunoglobulin variable-region-like domain (IgV), mucin-like domain, transmembrane domain, and intracellular tail^1,2. TIM-1 promotes activated T cell survival and plays a role in immunopathology². TIM-1 is also expressed by tubules injured by renal disease and in this context is known by its alternative name, kidney injury molecule-1 (KIM-1). Renal expression of TIM-1 is associated with dedifferentiation of epithelial cells and is involved in the phagocytosis of apoptotic debris. TIM-1 also plays a role in immune responses and is linked to airway hypersensitivity in mice and asthma, eczema, and rheumatoid arthritis in humans¹. TIM-1 was first identified as a hepatitis A virus cellular receptor¹. TIM-4 is a natural ligand of TIM-1.

RMT1-10 was generated by immunizing SD rats with full-length TIM-1-Ig containing both the IgV and mucin domains¹. Lymph nodes were fused with P3U1 myeloma cells. Resulting hybridomas were screened for binding to mouse TIM-1-transfected CHO cells.

RMT1-10 binds to full-length and mucinless forms of TIM-1, suggesting its epitope resides in the IgV domain¹. Blocking TIM-1 in culture via the addition of RMT1-10 results in reduced T cell proliferation, IFN-γ and IL-17 inhibition, and induction of the Th2 cytokines IL-4 and IL-10¹. Additionally, RMT1-10 significantly improves the survival rate of corneal allografts^3,4 and attenuates atherosclerosis development and progression by expanding atheroprotective B1a cells⁵ in mice.

TIM-1 is expressed on activated T cells, both Th1 and Th2 cells after CD4 + T cell polarization, and kidney cells.

Binds hepatitis A virus in humans, Tim-4, LMIR5/CD300b

1 Xiao S, Najafian N, Reddy J, et al. J Exp Med. 204(7):1691-1702. 2007.
2 Nozaki Y, Nikolic-Paterson DJ, Snelgrove SL, et al. Kidney Int. 81(9):844-55. 2012.
3 Guo YY, Yin CJ, Zhao M, et al. Eur Rev Med Pharmacol Sci. 23(21):9150-9162. 2019.
4 Tan X, Jie Y, Zhang Y, et al. Exp Eye Res. 122:86-932014.
5 Hosseini H, Yi L, Kanellakis P, et al. J Am Heart Assoc. 7(13):e008447. 2018.
6 Nozaki Y, Kitching AR, Akiba H, et al. Am J Physiol Renal Physiol. 306(10):F1210-21. 2014.
7 Zhang Y, Ji H, Shen X, et al. Am J Transplant. 13(1):56-66. 2013.